Bortezomib is the first therapeutic proteasome inhibitor to be tested in humans.
Proteasomes are cellular complexes that break down proteins. In some cancers ...
The Official Website for VELCADE® (bortezomib). ... VELCADE (bortezomib) is
approved for the treatment of people with multiple myeloma (a cancer of the ...
Easy to read patient leaflet for bortezomib. Includes indications, proper use,
special instructions, precautions, and possible side effects.
Oct 9, 2015 ... VELCADE® for Injection contains bortezomib which is an antineoplastic agent.
Bortezomib is a modified dipeptidyl boronic acid. The chemical ...
(bore TEZ oh mib). Trade name: Velcade<sup>®</sup>. Chemocare.com uses generic names
in all descriptions of drugs. Velcade is the trade name for Bortezomib. In some ...
Br J Haematol. 2016 Jun;173(5):779-85. doi: 10.1111/bjh.13993. Epub 2016 Mar
24. Bortezomib in the treatment of refractory thrombotic thrombocytopenic ...
Bortezomib (Velcade, Millennium Pharmaceuticals, Inc., Cambridge, MA, and
Johnson & Johnson Pharmaceutical Research & Development, L.L.C., Raritan,
Jun 13, 2005 ... The boron atom within bortezomib catalytically binds the active site of the 26S
proteasome with high affinity and specificity, thereby resulting in ...
Bortezomib (PS-341). Catalog No.S1013. 20 Reviews. Bortezomib (PS-341) is a
potent 20S proteasome inhibitor with Ki of 0.6 nM in a cell-free assay.
Feb 12, 2014 ... The biological therapy drug bortezomib (Velcade) is a treatment for myeloma.
The possible side effects include feeling or being sick; tiredness; ...